Veracyte (VCYT) Research & Development (2012 - 2026)

Veracyte (VCYT) has 15 years of Research & Development data on file, last reported at $27.1 million in Q1 2026.

• Quarterly Research & Development rose 52.92% year-over-year to $27.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.2 million (up 12.87% YoY) and the FY2025 annual result came in at $70.8 million, up 2.19% from the prior year.
• Research & Development rose to $27.1 million in Q1 2026 per VCYT's latest filing, from $20.8 million in the prior quarter.
• The five-year high for Research & Development was $27.1 million in Q1 2026, with the low at $9.2 million in Q1 2022.
• Average Research & Development over 5 years is $15.6 million, with a median of $16.0 million recorded in 2025.
• Year-over-year, Research & Development jumped 71.78% in 2022 and retreated 9.06% in 2025.
• Veracyte's Research & Development stood at $11.3 million in 2022, then jumped by 65.44% to $18.7 million in 2023, then gained by 3.3% to $19.3 million in 2024, then rose by 8.08% to $20.8 million in 2025, then advanced by 29.97% to $27.1 million in 2026.
• Business Quant data shows VCYT's Research & Development at $27.1 million in Q1 2026, $20.8 million in Q4 2025, and $16.0 million in Q3 2025.